Drug Trial Radar · NCT04437511
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,736
Actual
Start
Jun 19, 2020
Primary completion
Apr 14, 2023
Study completion Nov 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Jun 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab. Trial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up.
Conditions
- Alzheimer Disease
Interventions
DonanemabDrug
Given IV
PlaceboDrug
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)Time frame: Baseline, Week 76
- Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)Time frame: Baseline, Week 76
Locations
274 sites in 9 countries. Site status is shown where the registry gives one.
Gilbert Neurology
Gilbert, Arizona
Xenoscience
Phoenix, Arizona
Banner Alzheimer's Institute
Phoenix, Arizona
Perseverance Research Center
Scottsdale, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Banner Alzheimer's Institute Tucson
Tucson, Arizona
Center for Neurosciences
Tucson, Arizona
Health Initiatives Research
Fayetteville, Arkansas
North County Neurology Associates
Carlsbad, California
Wr- Pri, Llc
Encino, California
Neuro-Pain Medical Center
Fresno, California
Neurology Center of North Orange County
Fullerton, California
Irvine Clinical Research
Irvine, California
Kaizen Brain Center
La Jolla, California
Senior Clinical Trials, Inc.
Laguna Hills, California
Collaborative Neuroscience Research, LLC
Los Alamitos, California
USC Keck School of Medicine
Los Angeles, California
Clinical Research Institute
Los Angeles, California
Neurovations
Napa, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
Stanford Neuroscience Health Center
Palo Alto, California
SC3 Research - Pasadena
Pasadena, California
PCND Neurology
Poway, California
Anderson Clinical Research
Redlands, California
Artemis Institute for Clinical Research
San Diego, California
Pacific Research Network
San Diego, California
Sharp Neurocognitive Research Center
San Diego, California
UCSF Memory and Aging Center
San Francisco, California
Syrentis Clinical Research
Santa Ana, California
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California
Tilda Research
Tustin, California
Mountain Neurological Research Center
Basalt, Colorado
Alpine Clinical Research Center
Boulder, Colorado
Colorado Springs Neurological Associates
Colorado Springs, Colorado
Colorado Neurological Research Center, PC
Denver, Colorado
Institute for Neurodegenerative Disorders
New Haven, Connecticut
Yale University, Alzheimer's Disease Research Unit
New Haven, Connecticut
Research Center for Clinical Studies
Norwalk, Connecticut
Ki Health Partners, LLc, dba New England Institute for Clinical Research
Stamford, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
Showing 40 of 274 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.